The CFRI CF Community Voices Podcast

Role of Disrupted Airway-Surface Liquid (ASL) pH Regulation in Small Airways in CF Lung Disease Pathogenesis - Xiaopeng Li, PhD

Dr. Xiaopeng Li, Associate Professor in the Department of Pediatrics and Human Development in the College of Human Medicine at Michigan State University, presents research on impaired mucociliary transport and a lower airway-surface liquid (ASL) pH in CF small airways, and potential novel therapeutic target for small airways diseases. This presentation was part of CFRI's Virtual 34th National CF Education Conference on August 1, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

A Multi-‘Omic Approach to Evaluate Concurrent Sinus and Pulmonary Disease in Cystic Fibrosis - Keehoon Lee, PhD

Dr. Keehoon Lee, a postdoctoral scholar at the Pathogen and Microbiome Institute at Northern Arizona University, presents research on the microbial composition of upper and lower CF airways in patients with chronic rhinosinusitis. He highlights the relationship between microbiome composition and host response, such as specific gene expressions and their functions in disease control. This presentation was part of CFRI's Virtual 34th National CF Education Conference on August 1, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Advancing the GI Frontier for People with CF - Steven Freedman, MD, PhD

Dr. Steven Freedman, Director of the Pancreas Center at Beth Israel Deaconess Medical Center, Chief of the Division of Translational Research, and Professor of Medicine at Harvard Medical School, highlights the multiple GI manifestations that accompany cystic fibrosis. The presentation also discusses current trials and efforts to create best practice guidelines for clinicians. This presentation was part of CFRI's Virtual 34th National CF Education Conference on July 31, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Advances in Phage Therapy as a Treatment for Cystic Fibrosis - Benjamin Chan, PhD; Jon Koff, MD

Dr. Benjamin Chan, an Associate Research Scientist in the Department of Ecology and Evolutionary Biology at Yale University, and Dr. Jon Koff, Director of the Adult Cystic Fibrosis Program at Yale University, give a comprehensive overview on recent progress in phage therapy as a treatment for CF, including the development of a clinical trial to investigate the safety and efficacy of a nebulized personalized phage therapy approach and the establishment of a Center for Bacteriophage Research and Therapy at Yale. This presentation was part of CFRI's Virtual 34th National CF Education Conference on July 31, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Role of Disrupted Airway-Surface Liquid (ASL) pH Regulation in Small Airways in CF Lung Disease Pathogenesis - Xiaopeng Li, PhD (Audio)

Dr. Xiaopeng Li, Associate Professor in the Department of Pediatrics and Human Development in the College of Human Medicine at Michigan State University, presents research on impaired mucociliary transport and a lower airway-surface liquid (ASL) pH in CF small airways, and potential novel therapeutic target for small airways diseases. This presentation was part of CFRI's Virtual 34th National CF Education Conference on August 1, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

A Multi-‘Omic Approach to Evaluate Concurrent Sinus and Pulmonary Disease in Cystic Fibrosis - Keehoon Lee, PhD (Audio)

Dr. Keehoon Lee, a postdoctoral scholar at the Pathogen and Microbiome Institute at Northern Arizona University, presents research on the microbial composition of upper and lower CF airways in patients with chronic rhinosinusitis. He highlights the relationship between microbiome composition and host response, such as specific gene expressions and their functions in disease control. This presentation was part of CFRI's Virtual 34th National CF Education Conference on August 1, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Advancing the GI Frontier for People with CF - Steven Freedman, MD, PhD (Audio)

Dr. Steven Freedman, Director of the Pancreas Center at Beth Israel Deaconess Medical Center, Chief of the Division of Translational Research, and Professor of Medicine at Harvard Medical School, highlights the multiple GI manifestations that accompany cystic fibrosis. The presentation also discusses current trials and efforts to create best practice guidelines for clinicians. This presentation was part of CFRI's Virtual 34th National CF Education Conference on July 31, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Advances in Phage Therapy as a Treatment for Cystic Fibrosis - Benjamin Chan, PhD; Jon Koff, MD (Audio)

Dr. Benjamin Chan, an Associate Research Scientist in the Department of Ecology and Evolutionary Biology at Yale University, and Dr. Jon Koff, Director of the Adult Cystic Fibrosis Program at Yale University, give a comprehensive overview on recent progress in phage therapy as a treatment for CF, including the development of a clinical trial to investigate the safety and efficacy of a nebulized personalized phage therapy approach and the establishment of a Center for Bacteriophage Research and Therapy at Yale. This presentation was part of CFRI's Virtual 34th National CF Education Conference on July 31, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Q&A on Reproductive Health with Raksha Jain, MD, MSc

Dr. Raksha Jain, Associate Professor of Pulmonary and Critical Care Medicine and Director of the Adult CF Care Center at the University of Texas Southwestern in Dallas, answers follow-up questions on her presentation "Reproductive Health in Men and Women with CF" at CFRI's 34th National CF Education Conference. The Q&A was recorded on August 6, 2021.

Reproductive Health in Men and Women with CF: What Do We Know... - Raksha Jain, MD, MSc

Dr. Raksha Jain, Associate Professor of Pulmonary and Critical Care Medicine and Director of the Adult CF Care Center at the University of Texas Southwestern in Dallas, highlights what is known and unknown about male and female infertility in CF, contraception and its impact on health in CF, as well as pregnancy, lactation and parenthood for men and women with CF. The presentation also discusses the impact of highly effective CFTR modulators. This presentation was part of CFRI's Virtual 34th National CF Education Conference on August 1, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.